Recursion Pharmaceuticals. has been granted a patent for a method to identify target proteins using a test ligand. The process involves docking simulations, molecular data extraction, and binding site profile generation to identify candidate proteins, ultimately leading to the identification of a target protein for therapeutic applications. GlobalData’s report on Recursion Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Recursion Pharmaceuticals, Vehicle driver physiological monitoring was a key innovation area identified from patents. Recursion Pharmaceuticals's grant share as of June 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Method for identifying target proteins using ligands
The granted patent US12033723B2 outlines a method and system for identifying target proteins based on a test ligand through a series of computational simulations and analyses. The process begins with receiving a request from a computing device to identify a target protein. It involves conducting multiple docking simulations to identify a range of proteins that can bind with the test ligand and its analogous ligands. This is achieved by extracting molecular data from a reference database, identifying analogous ligands through molecular property comparisons, and analyzing protein data to find analogous-ligand protein complexes. The method further includes generating docking scores for these proteins, comparing them against predetermined thresholds, and creating binding site profiles to identify candidate proteins for further analysis.
Additionally, the patent describes the generation of a proteome binding profile for the identified target protein, which can be utilized to develop therapeutic treatments. The system comprises a data repository for storing structural data of protein surfaces and a server device that executes the necessary operations to perform the ligand-protein binding analysis. The method also emphasizes the importance of molecular fingerprints for identifying analogous ligands and includes provisions for displaying the target protein and its binding sites to client devices. Overall, this patent presents a comprehensive approach to protein identification that leverages advanced computational techniques to enhance drug discovery and therapeutic development.
To know more about GlobalData’s detailed insights on Recursion Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
